Nonalcoholic Fatty Liver Disease (NAFLD)

Last Updated: August 16, 2022

Non-alcoholic fatty liver disease (NAFLD) is a condition in which excessive fat (more than 5% of liver weight) accumulates in the liver due to causes unrelated to alcohol.

Nonalcoholic Fatty Liver Disease (NAFLD) falls under theLiver HealthandHealthy Aging & Longevitycategories.

What is NAFLD?

Nonalcoholic fatty liver disease (NAFLD) refers to a spectrum of liver diseases characterized by an excessive accumulation of fat in the liver without excessive alcohol consumption (i.e., > 21 standard drinks per week for men and > 14 standard drinks per week for women). It can be broadly divided into nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). NAFL is less severe and only includes excessive liver fat (i.e., the presence of fat in > 5% of liver cells), whereas NASH includes excessive liver fat plus liver inflammation and damage.

What are the main signs and symptoms of NAFLD?

Most people with NAFLD do not present with symptoms, and the disease remains silent until it has progressed to an advanced stage. In the early stages, fatigue and upper abdominal pain may be reported. Elevated levels of serum alanine aminotransferase and aspartate aminotransferase are also typically observed. In cases of very severe NAFLD, jaundice (i.e., yellowing of the eyes and skin), edema, ascites (i.e., excess fluid trapped in the abdomen), and/or confusion may be present.

How is NAFLD diagnosed?

Liver biopsy is considered the gold standard for diagnosing NAFLD and is essential for diagnosing NASH, as it is the only procedure that can reliably differentiate it from NAFL.[1] Imaging methods, such as ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI), are more commonly used, but their ability to detect mild NAFL is poor. MRI seems to be the precise imaging method.[2]

What are some of the main medical treatments for NAFLD?

There are no Food and Drug Administration-approved medications for treating NAFLD. Current guidelines suggest that pharmacological treatment should be reserved for people with biopsy-proven NASH.[3] Off-label medications are mainly used for treating risk factors (i.e., obesity, insulin resistance, hypertension, dyslipidemia) with the aim of preventing disease progression.

Have any supplements been studied for NAFLD?

Vitamin E seems to be the most compelling supplement for treating NAFLD.[4] There is evidence to support the use of omega-3 polyunsaturated fatty acids as well.[5]

How could diet affect NAFLD?

Lifestyle modification with the aim of inducing weight loss is the cornerstone of NAFLD treatment. A weight loss of at least 5% of initial body weight is effective for reducing liver fat, and a weight loss of 7–10% can improve features of NASH.[3] In this respect, the macronutrient composition of the diet is much less important than the energy content; an array of dietary patterns can be effective as long as they facilitate sustained weight loss.

Are there any other treatments for NAFLD?

An increase in physical activity is recommended alongside dietary changes to achieve significant weight loss.[1][3] Exercise can also decrease liver fat irrespective of changes in body weight.[6]

What causes NAFLD?

NAFLD reflects an imbalance of energy metabolism in the liver: more energy enters the liver than it can dispose of, resulting in a net accumulation of energy as triglycerides.[7] Overnutrition and sedentary behavior primarily lead to the development of NAFLD, but there are a variety of other factors that further influence the development and progression of the disease, including genetics, aging, fat tissue dysfunction, gut dysbiosis, and insulin resistance.[8][9]

Looking for a Supplement guide?

Our Supplement Guides give you unbiased research-based recommendations that you can immediately apply to improve your health. Nonalcoholic Fatty Liver Disease (NAFLD) is related to the following Supplement Guide:
Examine Database: Nonalcoholic Fatty Liver Disease (NAFLD)
What works and what doesn't?

Unlock the full potential of Examine

Get started

Don't miss out on the latest research

  1. ^European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver diseaseJ Hepatol.(2016 Jun)
  2. ^Yingzhen N Zhang, Kathryn J Fowler, Gavin Hamilton, Jennifer Y Cui, Ethan Z Sy, Michelle Balanay, Jonathan C Hooker, Nikolaus Szeverenyi, Claude B SirlinLiver fat imaging-a clinical overview of ultrasound, CT, and MR imagingBr J Radiol.(2018 Sep)
  3. ^Naga Chalasani, Zobair Younossi, Joel E Lavine, Michael Charlton, Kenneth Cusi, Mary Rinella, Stephen A Harrison, Elizabeth M Brunt, Arun J SanyalThe diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver DiseasesHepatology.(2018 Jan)
  4. ^Andreas Vadarlis, Christina Antza, Dimitra Rafailia Bakaloudi, Ioannis Doundoulakis, Georgios Kalopitas, Myrto Samara, Theodoros Dardavessis, Theofanis Maris, Michail ChourdakisSystematic review with meta-analysis: The effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver diseaseJ Gastroenterol Hepatol.(2021 Feb)
  5. ^Veronika A Prikhodko, Natalia N Bezborodkina, Sergey V OkovityiPharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug CandidatesBiomedicines.(2022 Jan 26)
  6. ^Christina N Katsagoni, Michael Georgoulis, George V Papatheodoridis, Demosthenes B Panagiotakos, Meropi D KontogianniEffects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysisMetabolism.(2017 Mar)
  7. ^Rohit Loomba, Scott L Friedman, Gerald I ShulmanMechanisms and disease consequences of nonalcoholic fatty liver diseaseCell.(2021 May 13)
  8. ^Elena Buzzetti, Massimo Pinzani, Emmanuel A TsochatzisThe multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)Metabolism.(2016 Aug)
  9. ^Norbert Stefan, Hans-Ulrich Häring, Kenneth CusiNon-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategiesLancet Diabetes Endocrinol.(2019 Apr)
  10. ^Zhong S, Fan Y, Yan Q, Fan X, Wu B, Han Y, Zhang Y, Chen Y, Zhang H, Niu JThe therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: A meta-analysis (PRISMA) of randomized control trialsMedicine (Baltimore).(2017 Dec)
  11. ^Voroneanu L, Nistor I, Dumea R, Apetrii M, Covic ASilymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsJ Diabetes Res.(2016)
  12. ^Yan HM, Xia MF, Wang Y, Chang XX, Yao XZ, Rao SX, Zeng MS, Tu YF, Feng R, Jia WP, Liu J, Deng W, Jiang JD, Gao XEfficacy of Berberine in Patients with Non-Alcoholic Fatty Liver DiseasePLoS One.(2015 Aug 7)
  13. ^Spengler EK, Loomba RRecommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic SteatohepatitisMayo Clin Proc.(2015 Sep)
  14. ^Mohammed Eslam, Philip N Newsome, Shiv K Sarin, Quentin M Anstee, Giovanni Targher, Manuel Romero-Gomez, Shira Zelber-Sagi, Vincent Wai-Sun Wong, Jean-François Dufour, Jörn M Schattenberg, Takumi Kawaguchi, Marco Arrese, Luca Valenti, Gamal Shiha, Claudio Tiribelli, Hannele Yki-Järvinen, Jian-Gao Fan, Henning Grønbæk, Yusuf Yilmaz, Helena Cortez-Pinto, Claudia P Oliveira, Pierre Bedossa, Leon A Adams, Ming-Hua Zheng, Yasser Fouad, Wah-Kheong Chan, Nahum Mendez-Sanchez, Sang Hoon Ahn, Laurent Castera, Elisabetta Bugianesi, Vlad Ratziu, Jacob GeorgeA new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statementJ Hepatol.(2020 Jul)
  15. ^Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba RFibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.Clin Gastroenterol Hepatol.(2015-Apr)
  16. ^McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QMEvidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.J Hepatol.(2015-May)
  17. ^Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, Hanratty BMetabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies.PLoS Med.(2020-04)
  18. ^Chen J, Song S, Li X, Bian D, Wu XAssociation of metabolic traits with occurrence of nonalcoholic fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis of longitudinal cohort studies.Saudi J Gastroenterol.(2022)
  19. ^Qing Ye, Biyao Zou, Yee Hui Yeo, Jie Li, Daniel Q Huang, Yuankai Wu, Hongli Yang, Chuanli Liu, Leslie Y Kam, Xiang Xuan Eunice Tan, Nicholas Chien, Sam Trinh, Linda Henry, Christopher Donald Stave, Tetsuya Hosaka, Ramsey C Cheung, Mindie H NguyenGlobal prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysisLancet Gastroenterol Hepatol.(2020 Aug)
  20. ^Eslam M, El-Serag HB, Francque S, Sarin SK, Wei L, Bugianesi E, George JMetabolic (dysfunction)-associated fatty liver disease in individuals of normal weight.Nat Rev Gastroenterol Hepatol.(2022-Jun-16)
  21. ^Isabel Errazuriz, Simmi Dube, Michael Slama, Roberto Visentin, Sunita Nayar, Helen O'Connor, Claudio Cobelli, Swapan Kumar Das, Ananda Basu, Walter Karl Kremers, John Port, Rita BasuRandomized Controlled Trial of a MUFA or Fiber-Rich Diet on Hepatic Fat in PrediabetesJ Clin Endocrinol Metab.(2017 May 1)
  22. ^Lutgarda Bozzetto, Anna Prinster, Giovanni Annuzzi, Lucia Costagliola, Anna Mangione, Alessandra Vitelli, Raffaella Mazzarella, Margaret Longobardo, Marcello Mancini, Carlo Vigorito, Gabriele Riccardi, Angela A RivelleseLiver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patientsDiabetes Care.(2012 Jul)
  23. ^Fredrik Rosqvist, Joel Kullberg, Marcus Ståhlman, Jonathan Cedernaes, Kerstin Heurling, Hans-Erik Johansson, David Iggman, Helena Wilking, Anders Larsson, Olof Eriksson, Lars Johansson, Sara Straniero, Mats Rudling, Gunnar Antoni, Mark Lubberink, Marju Orho-Melander, Jan Borén, Håkan Ahlström, Ulf RisérusOvereating Saturated Fat Promotes Fatty Liver and Ceramides Compared With Polyunsaturated Fat: A Randomized TrialJ Clin Endocrinol Metab.(2019 Dec 1)
  24. ^Rosqvist F, Iggman D, Kullberg J, Cedernaes J, Johansson HE, Larsson A, Johansson L, Ahlström H, Arner P, Dahlman I, Risérus UOverfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humansDiabetes.(2014 Jul)
  25. ^Luukkonen PK, Sädevirta S, Zhou Y, Kayser B, Ali A, Ahonen L, Lallukka S, Pelloux V, Gaggini M, Jian C, Hakkarainen A, Lundbom N, Gylling H, Salonen A, Orešič M, Hyötyläinen T, Orho-Melander M, Rissanen A, Gastaldelli A, Clément K, Hodson L, Yki-Järvinen HSaturated Fat Is More Metabolically Harmful for the Human Liver Than Unsaturated Fat or Simple Sugars.Diabetes Care.(2018-08)
  26. ^Bjermo H, Iggman D, Kullberg J, Dahlman I, Johansson L, Persson L, Berglund J, Pulkki K, Basu S, Uusitupa M, Rudling M, Arner P, Cederholm T, Ahlström H, Risérus UEffects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trialAm J Clin Nutr.(2012 May)
  27. ^Sophie Schutte, Diederik Esser, Els Siebelink, Charlotte J R Michielsen, Monique Daanje, Juri C Matualatupauw, Hendriek C Boshuizen, Marco Mensink, Lydia A Afman, Wageningen Belly Fat Study teamDiverging metabolic effects of two energy restricted diets differing in nutrient quality: a 12-week randomized controlled trial in subjects with abdominal obesityAm J Clin Nutr.(2022 Jan 31)
  28. ^Mads J Skytte, Amirsalar Samkani, Amy D Petersen, Mads N Thomsen, Arne Astrup, Elizaveta Chabanova, Jan Frystyk, Jens J Holst, Henrik S Thomsen, Sten Madsbad, Thomas M Larsen, Steen B Haugaard, Thure KrarupA carbohydrate-reduced high-protein diet improves HbA 1c and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trialDiabetologia.(2019 Nov)
  29. ^Chenchen Xu, Mariya Markova, Nicole Seebeck, Anne Loft, Silke Hornemann, Thomas Gantert, Stefan Kabisch, Kathleen Herz, Jennifer Loske, Mario Ost, Verena Coleman, Frederick Klauschen, Anke Rosenthal, Volker Lange, Jürgen Machann, Susanne Klaus, Tilman Grune, Stephan Herzig, Olga Pivovarova-Ramich, Andreas F H PfeifferHigh-protein diet more effectively reduces hepatic fat than low-protein diet despite lower autophagy and FGF21 levelsLiver Int.(2020 Jul 11)
  30. ^Theytaz F, Noguchi Y, Egli L, Campos V, Buehler T, Hodson L, Patterson BW, Nishikata N, Kreis R, Mittendorfer B, Fielding B, Boesch C, Tappy LEffects of supplementation with essential amino acids on intrahepatic lipid concentrations during fructose overfeeding in humans.Am J Clin Nutr.(2012-Nov)
  31. ^Bortolotti M, Kreis R, Debard C, Cariou B, Faeh D, Chetiveaux M, Ith M, Vermathen P, Stefanoni N, Lê KA, Schneiter P, Krempf M, Vidal H, Boesch C, Tappy LHigh protein intake reduces intrahepatocellular lipid deposition in humansAm J Clin Nutr.(2009 Oct)
  32. ^Bortolotti M, Maiolo E, Corazza M, Van Dijke E, Schneiter P, Boss A, Carrel G, Giusti V, Lê KA, Quo Chong DG, Buehler T, Kreis R, Boesch C, Tappy LEffects of a whey protein supplementation on intrahepatocellular lipids in obese female patientsClin Nutr.(2011 Aug)
  33. ^Maria Maersk, Anita Belza, Hans Stødkilde-Jørgensen, Steffen Ringgaard, Elizaveta Chabanova, Henrik Thomsen, Steen B Pedersen, Arne Astrup, Bjørn RichelsenSucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention studyAm J Clin Nutr.(2012 Feb)
  34. ^Desiree M Sigala, Bettina Hieronimus, Valentina Medici, Vivien Lee, Marinelle V Nunez, Andrew A Bremer, Chad L Cox, Candice A Price, Yanet Benyam, Abhijit J Chaudhari, Yasser Abdelhafez, John P McGahan, Michael Goran, Claude B Sirlin, Giovanni Pacini, Andrea Tura, Nancy L Keim, Peter J Havel, Kimber L StanhopeConsuming Sucrose- or HFCS-Sweetened Beverages Increases Hepatic Lipid and Decreases Insulin Sensitivity in AdultsJ Clin Endocrinol Metab.(2021 Jul 15)
  35. ^Jean-Marc Schwarz, Susan M Noworolski, Michael J Wen, Artem Dyachenko, Jessica L Prior, Melissa E Weinberg, Laurie A Herraiz, Viva W Tai, Nathalie Bergeron, Thomas P Bersot, Madhu N Rao, Morris Schambelan, Kathleen MulliganEffect of a High-Fructose Weight-Maintaining Diet on Lipogenesis and Liver FatJ Clin Endocrinol Metab.(2015 Jun)
  36. ^Lecoultre V, Egli L, Carrel G, Theytaz F, Kreis R, Schneiter P, Boss A, Zwygart K, Lê KA, Bortolotti M, Boesch C, Tappy LEffects of fructose and glucose overfeeding on hepatic insulin sensitivity and intrahepatic lipids in healthy humans.Obesity (Silver Spring).(2013-Apr)
  37. ^Catherine C Cohen, Kelvin W Li, Adina L Alazraki, Carine Beysen, Carissa A Carrier, Rebecca L Cleeton, Mohamad Dandan, Janet Figueroa, Jack Knight-Scott, Cynthia J Knott, Kimberly P Newton, Edna M Nyangau, Claude B Sirlin, Patricia A Ugalde-Nicalo, Jean A Welsh, Marc K Hellerstein, Jeffrey B Schwimmer, Miriam B VosDietary sugar restriction reduces hepatic de novo lipogenesis in adolescent boys with fatty liver diseaseJ Clin Invest.(2021 Dec 15)
  38. ^Ibarra-Reynoso LDR, López-Lemus HL, Garay-Sevilla ME, Malacara JMEffect of Restriction of Foods with High Fructose Corn Syrup Content on Metabolic Indices and Fatty Liver in Obese Children.Obes Facts.(2017)
  39. ^Jean-Marc Schwarz, Susan M Noworolski, Ayca Erkin-Cakmak, Natalie J Korn, Michael J Wen, Viva W Tai, Grace M Jones, Sergiu P Palii, Moises Velasco-Alin, Karen Pan, Bruce W Patterson, Alejandro Gugliucci, Robert H Lustig, Kathleen MulliganEffects of Dietary Fructose Restriction on Liver Fat, De Novo Lipogenesis, and Insulin Kinetics in Children With ObesityGastroenterology.(2017 Sep)
  40. ^Nynke Simons, Pandichelvam Veeraiah, Pomme I H G Simons, Nicolaas C Schaper, M Eline Kooi, Vera B Schrauwen-Hinderling, Edith J M Feskens, E M C Liesbeth van der Ploeg, Mathias D G Van den Eynde, Casper G Schalkwijk, Coen D A Stehouwer, Martijn C G J BrouwersEffects of fructose restriction on liver steatosis (FRUITLESS); a double-blind randomized controlled trialAm J Clin Nutr.(2020 Dec 31)
  41. ^Karoline Sandby, Nina Rica Wium Geiker, Maria Dalamaga, Henning Grønbæk, Faidon MagkosEfficacy of Dietary Manipulations for Depleting Intrahepatic Triglyceride Content: Implications for the Management of Non-alcoholic Fatty Liver DiseaseCurr Obes Rep.(2021 Jun)
  42. ^Bawden S, Stephenson M, Falcone Y, Lingaya M, Ciampi E, Hunter K, Bligh F, Schirra J, Taylor M, Morris P, Macdonald I, Gowland P, Marciani L, Aithal GPIncreased liver fat and glycogen stores after consumption of high versus low glycaemic index food: A randomized crossover study.Diabetes Obes Metab.(2017-01)
  43. ^Agebratt C, Ström E, Romu T, Dahlqvist-Leinhard O, Borga M, Leandersson P, Nystrom FHA Randomized Study of the Effects of Additional Fruit and Nuts Consumption on Hepatic Fat Content, Cardiovascular Risk Factors and Basal Metabolic Rate.PLoS One.(2016)
  44. ^Alami F, Alizadeh M, Shateri KThe effect of a fruit-rich diet on liver biomarkers, insulin resistance, and lipid profile in patients with non-alcoholic fatty liver disease: a randomized clinical trial.Scand J Gastroenterol.(2022-Oct)
  45. ^Wallace TC, Bailey RL, Blumberg JB, Burton-Freeman B, Chen CO, Crowe-White KM, Drewnowski A, Hooshmand S, Johnson E, Lewis R, Murray R, Shapses SA, Wang DDFruits, vegetables, and health: A comprehensive narrative, umbrella review of the science and recommendations for enhanced public policy to improve intake.Crit Rev Food Sci Nutr.(2020)
  46. ^Kenneth Cusi, Scott Isaacs, Diana Barb, Rita Basu, Sonia Caprio, W Timothy Garvey, Sangeeta Kashyap, Jeffrey I Mechanick, Marialena Mouzaki, Karl Nadolsky, Mary E Rinella, Miriam B Vos, Zobair YounossiAmerican Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)Endocr Pract.(2022 May)
  47. ^Plauth M, Bernal W, Dasarathy S, Merli M, Plank LD, Schütz T, Bischoff SCESPEN guideline on clinical nutrition in liver disease.Clin Nutr.(2019-04)
  48. ^Younossi ZM, Corey KE, Lim JKAGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review.Gastroenterology.(2021-02)
  49. ^Martínez-González MA, Gea A, Ruiz-Canela MThe Mediterranean Diet and Cardiovascular Health.Circ Res.(2019-03)
  50. ^Shira Zelber-Sagi, Federico Salomone, Liat MlynarskyThe Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanismsLiver Int.(2017 Jul)
  51. ^Elena S George, Anjana Reddy, Amanda J Nicoll, Marno C Ryan, Catherine Itsiopoulos, Gavin Abbott, Nathan A Johnson, Siddharth Sood, Stuart K Roberts, Audrey C TierneyImpact of a Mediterranean diet on hepatic and metabolic outcomes in non-alcoholic fatty liver disease: The MEDINA randomised controlled trialLiver Int.(2022 Mar 31)
  52. ^Marno C Ryan, Catherine Itsiopoulos, Tania Thodis, Glenn Ward, Nicholas Trost, Sophie Hofferberth, Kerin O'Dea, Paul V Desmond, Nathan A Johnson, Andrew M WilsonThe Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver diseaseJ Hepatol.(2013 Jul)
  53. ^Utzschneider KM, Bayer-Carter JL, Arbuckle MD, Tidwell JM, Richards TL, Craft SBeneficial effect of a weight-stable, low-fat/low-saturated fat/low-glycaemic index diet to reduce liver fat in older subjects.Br J Nutr.(2013-Mar-28)
  54. ^Westerbacka J, Lammi K, Häkkinen AM, Rissanen A, Salminen I, Aro A, Yki-Järvinen HDietary fat content modifies liver fat in overweight nondiabetic subjects.J Clin Endocrinol Metab.(2005-May)
Examine Database References
  1. Blood glucose - Cicero AFG, Sahebkar A, Fogacci F, Bove M, Giovannini M, Borghi CEffects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: a double-blind, placebo-controlled clinical trialEur J Nutr.(2019 Feb 22)
  2. Blood glucose - Jazayeri-Tehrani SA, Rezayat SM, Mansouri S, Qorbani M, Alavian SM, Daneshi-Maskooni M, Hosseinzadeh-Attar MJNano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trialNutr Metab (Lond).(2019 Jan 28)
  3. Blood glucose - Saeede Saadati, Behzad Hatami, Zahra Yari, Mohammad Amin Shahrbaf, Sareh Eghtesad, Asieh Mansour, Hossein Poustchi, Mehdi Hedayati, Morteza Aghajanpoor-Pasha, Amir Sadeghi, Azita HekmatdoostThe effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver diseaseEur J Clin Nutr.(2019 Mar)
  4. Blood glucose - Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendía LE, Sahebkar ACurcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled TrialJ Cardiovasc Pharmacol.(2016 Sep)
  5. Blood glucose - Navekar R, Rafraf M, Ghaffari A, Asghari-Jafarabadi M, Khoshbaten MTurmeric Supplementation Improves Serum Glucose Indices and Leptin Levels in Patients with Nonalcoholic Fatty Liver DiseasesJ Am Coll Nutr.(2017 May-Jun)
  6. Low-density lipoprotein (LDL) - Rahmani S, Asgary S, Askari G, Keshvari M, Hatamipour M, Feizi A, Sahebkar ATreatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled TrialPhytother Res.(2016 Sep)
  7. Total cholesterol - M H Ngu, M N Norhayati, Z Rosnani, M M ZulkifliCurcumin as adjuvant treatment in patients with non-alcoholic fatty liver (NAFLD) disease: A systematic review and meta-analysisComplement Ther Med.(2022 Sep)
  8. Weight - Nima Baziar, Mohammad ParohanThe effects of curcumin supplementation on body mass index, body weight, and waist circumference in patients with nonalcoholic fatty liver disease: A systematic review and dose-response meta-analysis of randomized controlled trialsPhytother Res.(2020 Mar)
  9. Weight - Jafarirad S, Mansoori A, Adineh A, Panahi Y, Hadi A, Goodarzi RDoes Turmeric/curcumin Supplementation Change Anthropometric Indices in Patients with Non-alcoholic Fatty Liver Disease? A Systematic Review and Meta-analysis of Randomized Controlled Trials.Clin Nutr Res.(2019-Jul)
  10. Blood glucose - Fabbrini E, Mohammed BS, Korenblat KM, Magkos F, McCrea J, Patterson BW, Klein SEffect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver diseaseJ Clin Endocrinol Metab.(2010 Jun)
  11. Blood glucose - Yan HM, Xia MF, Wang Y, Chang XX, Yao XZ, Rao SX, Zeng MS, Tu YF, Feng R, Jia WP, Liu J, Deng W, Jiang JD, Gao XEfficacy of Berberine in Patients with Non-Alcoholic Fatty Liver DiseasePLoS One.(2015 Aug 7)
  12. Blood Pressure - Zamani M, Zarei M, Nikbaf-Shandiz M, Hosseini S, Shiraseb F, Asbaghi OThe effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.Front Nutr.(2022)
  13. Blood glucose - Alavinejad P, et alEvaluation of L-Carnitine Efficacy in the Treatment of Non-Alcoholic Fatty Liver Disease among Diabetic Patients: A Randomized Double Blind Pilot StudyJ Gastroenterol Hepatol.()
  14. Low-density lipoprotein (LDL) - Liu A, Cai Y, Yuan Y, Liu M, Zhang Z, Xu Y, Jiao PEfficacy and safety of carnitine supplementation on NAFLD: a systematic review and meta-analysis.Syst Rev.(2023-Apr-29)
  15. Liver Fat - Mohamad Hosein Somi, Ebrahim Fatahi, Jafar Panahi, Mohamad Reza Havasian, Arezo JudakiData from a randomized and controlled trial of LCarnitine prescription for the treatment for Non- Alcoholic Fatty Liver DiseaseBioinformation.(2014 Sep 30)
  16. Glycemic Control - Chou SC, Chen KW, Hwang JS, Lu WT, Chu YY, Lin JD, Chang HJ, See LCThe add-on effects of Gynostemma pentaphyllum on nonalcoholic fatty liver diseaseAltern Ther Health Med.(2006 May-Jun)
  17. Glycemic Control - Akinkuolie AO, Ngwa JS, Meigs JB, Djoussé LOmega-3 polyunsaturated fatty acid and insulin sensitivity: a meta-analysis of randomized controlled trialsClin Nutr.(2011 Dec)
  18. Glycemic Control - Nobili V, Bedogni G, Alisi A, Pietrobattista A, Risé P, Galli C, Agostoni CDocosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trialArch Dis Child.(2011 Apr)
  19. Blood Pressure - Abidov M, Ramazanov Z, Seifulla R, Grachev SThe effects of Xanthigen in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fatDiabetes Obes Metab.(2010 Jan)
  20. Low-density lipoprotein (LDL) - Ferreira-Hermosillo A, Torres-Duran PV, Juarez-Oropeza MAHepatoprotective effects of Spirulina maxima in patients with non-alcoholic fatty liver disease: a case seriesJ Med Case Rep.(2010 Apr 7)
  21. Low-density lipoprotein (LDL) - Elias E Mazokopakis, Maria G Papadomanolaki, Andreas A Fousteris, Dimitrios A Kotsiris, Ioannis M Lampadakis, Emmanuel S GanotakisThe hepatoprotective and hypolipidemic effects of Spirulina ( Arthrospira platensis) supplementation in a Cretan population with non-alcoholic fatty liver disease: a prospective pilot studyAnn Gastroenterol.(2014)
  22. Liver Fat - Zahra Darabi, Mina Darand, Zahra Yari, Mehdi Hedayati, Amirhosein Faghihi, Shahram Agah, Azita HekmatdoostInflammatory markers response to citrulline supplementation in patients with non-alcoholic fatty liver disease: a randomized, double blind, placebo-controlled, clinical trialBMC Res Notes.(2019 Feb 15)
  23. Liver Fat - Abdelmalek MF, Sanderson SO, Angulo P, Soldevila-Pico C, Liu C, Peter J, Keach J, Cave M, Chen T, McClain CJ, Lindor KDBetaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trialHepatology.(2009 Dec)
  24. Liver Enzymes - Georgios Kalopitas, Christina Antza, Ioannis Doundoulakis, Antonis Siargkas, Elias Kouroumalis, Georgios Germanidis, Myrto Samara, Michail ChourdakisImpact of Silymarin in individuals with nonalcoholic fatty liver disease: A systematic review and meta-analysisNutrition.(2021 Mar)
  25. Liver Enzymes - Zhong S, Fan Y, Yan Q, Fan X, Wu B, Han Y, Zhang Y, Chen Y, Zhang H, Niu JThe therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: A meta-analysis (PRISMA) of randomized control trialsMedicine (Baltimore).(2017 Dec)
  26. Liver Enzymes - Kailin Yang, Junpeng Chen, Tianqing Zhang, Xiao Yuan, Anqi Ge, Shanshan Wang, Hao Xu, Liuting Zeng, Jinwen GeEfficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysisFront Immunol.(2022 Sep 9)
  27. Liver Enzymes - Fakhri M, Fakheri H, Azadbakht M, Moosazadeh M, Yousefi SSEffect of Medicinal Plants and Natural Products on Liver Enzymes in Non-alcoholic Fatty Liver Patients in Iran: A Systematic Review and Meta-Analysis.Int J Prev Med.(2022)
  28. Liver Enzymes - de Avelar CR, Pereira EM, de Farias Costa PR, de Jesus RP, de Oliveira LPMEffect of silymarin on biochemical indicators in patients with liver disease: Systematic review with meta-analysis.World J Gastroenterol.(2017-Jul-21)
  29. Liver Enzymes - Medici V, Virata MC, Peerson JM, Stabler SP, French SW, Gregory JF 3rd, Albanese A, Bowlus CL, Devaraj S, Panacek EA, Richards JR, Halsted CHS-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trialAlcohol Clin Exp Res.(2011 Nov)
  30. Liver Enzymes - Meegun Hong, Yoon Hyeong Lee, Seungwoo Kim, Ki Tae Suk, Chang Seok Bang, Jai Hoon Yoon, Gwang Ho Baik, Dong Joon Kim, Myong Jo KimAnti-inflammatory and antifatigue effect of Korean Red Ginseng in patients with nonalcoholic fatty liver diseaseJ Ginseng Res.(2016 Jul)
  31. Cirrhosis Severity - Somi MH, Rezaeifar P, Ostad Rahimi A, Moshrefi BEffects of low dose zinc supplementation on biochemical markers in non-alcoholic cirrhosis: a randomized clinical trialArch Iran Med.(2012 Aug)
  32. Malondialdehyde (MDA) - Morvaridzadeh M, Estêvão MD, Qorbani M, Heydari H, Hosseini AS, Fazelian S, Belančić A, Persad E, Rezamand G, Heshmati JThe effect of chromium intake on oxidative stress parameters: A systematic review and meta-analysis.J Trace Elem Med Biol.(2022-Jan)